Archive | Hot Mandates RSS feed for this section

Hot Investor Mandate: Biotech and Healthcare Focused Incubator and Investment Firm Invests from Seed to Pre-IPO Rounds Across the Globe

10 Feb

An investment firm and incubator is focused on biotechnology and healthcare. The firm prefers to participate in early-stage and Seed financings as well as later-stage and pre-IPO rounds. The firm typically makes a limited number of investments per year, with initial allocation sizes generally ranging from $500K to $5M for early-stage opportunities and approximately $2M to $10M for later-stage investments. The firm utilizes flexible capital structures on a case-by-case basis and has experience with both equity investments and convertible loans. While the firm primarily invests in U.S.-based companies, the firm is open to evaluating opportunities globally.  

The firm is primarily interested in biotechnology therapeutics and medical technology. The firm considers a wide range of therapeutic modalities and has particular expertise in molecule development, while generally avoiding medical devices and digital health. The firm will evaluate diagnostic opportunities but prefers a focus on genomics and biomarker-based diagnostics. The firm considers therapeutics at the preclinical stage through Phase I, Phase II, and Phase III clinical development, as well as medical technology and diagnostics that are in development or clinical stages. The firm is disease-agnostic and evaluates opportunities across indications, with prior experience in oncology and autoimmune-related technologies.  

From a company and management team perspective, the firm prefers to partner with experienced management teams that are fully dedicated to their technology and company. The firm is an active investor and may take a board seat on a case-by-case basis depending on investment size. The firm is open to acting as both a lead investor and a co-investor. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , , , ,

Hot Investor Mandate: Europe-Based VC Invests in Pre-Seed and Seed Stage Companies in the Intersection of Deeptech and Life Sciences

10 Feb

A venture capital firm that historically focused on deep-tech and hardware is now expanding its scope to opportunities at the intersection of deep-tech and life sciences. The firm is currently investing from its second fund, sized at approximately USD $75M. The firm participates in Pre-Seed and Seed financing rounds, with typical allocations ranging from USD $500K to $2.5M. The firm prefers to lead or co-lead investment rounds and evaluates opportunities across Europe and the United States.  

Within life sciences, the firm is open to digital health deep-tech companies but does not invest in application-only businesses. The firm does not pursue traditional therapeutics but will consider therapeutics that incorporate a strong data component, as well as multi-asset or platform-based technologies. The firm is also interested in diagnostics, non-invasive medical devices, surgical tools, and biomanufacturing. The firm focuses on companies at the pre-clinical and early development stages and is disease-agnostic.  

The firm does not impose strict requirements on companies or management teams. The firm may consider taking a board seat or observer seat on a case-by-case basis. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: USA-Based VC Firm Actively Invests in Seed to Series A AI and Computational-Driven Techbio Companies

3 Feb

The firm is a U.S.-based venture capital platform providing smart capital to early-stage companies in medicine, biotech, and bioengineering. The firm focuses on opportunities at the intersection of biotechnology and computation or AI. The firm’s investment sweet spot is between Seed and Series A, with initial check sizes typically ranging from $250K–$300K and up to $500K, with the potential for follow-on investments. The firm is open to both leading and co-investing and does not have specific requirements regarding board or observer seats. The firm primarily focuses on companies based in the United States.  

The firm invests in techbio opportunities that combine biotechnology with computational or AI-driven approaches. The firm is less interested in digital health companies that do not have a biotech or wet-lab component and prioritizes highly innovative technologies with novel mechanisms rather than incremental improvements. Modalities of interest include gene therapy, cell therapy, mRNA-based therapies, and platform technologies. The firm is indication-agnostic. From a development-stage perspective, the firm is most interested in assets at the preclinical stage or entering early clinical development, supported by in vitro and/or animal model data.  

The firm does not have specific requirements regarding the composition of a company’s management team. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Multi-Stage Investment Firm Seeks Early and Growth-Stage Companies Across All Life Science and Healthcare Sectors

3 Feb

A multi-stage healthcare and life sciences investment platform is focused on addressing areas of significant unmet medical need by backing companies across all stages of development. The firm applies a data science–driven investment approach, prioritizing businesses that leverage biology and large-scale data to transform healthcare delivery and outcomes.  

The firm is broadly interested across the healthcare landscape, including medical technology, therapeutics, diagnostics, laboratory equipment, healthcare IT, and R&D services. Within medical technology, the firm seeks companies with at least an alpha-stage prototype supported by initial efficacy data. Within therapeutics, the firm primarily targets assets in Phase II clinical development and will consider Phase I programs only when supported by clear efficacy data.  

From a company and management team perspective, the firm looks for a strong and capable management team to be in place. The firm is open to investing in both privately held and publicly traded companies. For private investments, the firm generally seeks to take a board seat. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: VC Firm Invests in Seed-Stage Life Science Companies in North America and Europe Addressing Age-Related Diseases

3 Feb

A venture capital platform with a dedicated life sciences fund is focused on Seed-stage investments. The fund typically invests around $1M per company and does not have a strict preference between leading rounds or co-investing. The firm is open to opportunities across North America and Europe.  

Within life sciences, the fund focuses on therapeutics, medtech, digital health, and broader biotech ecosystem companies addressing age-related diseases. Areas of interest include cardiovascular disease, cancer, respiratory illnesses, dementia, Alzheimer’s disease, diabetes, and kidney disease.  

Within therapeutics, the fund emphasizes “repair and replace” approaches, including regenerative medicine, gene therapy, and immunotherapy. In medtech, the fund is interested in wearables, biosensors, and remote patient monitoring technologies. In digital health, areas of focus include AI-driven drug discovery and solutions that optimize clinical trial execution. Within the biotech ecosystem, the fund is drawn to bioprinting, biomaterials, and drug delivery platforms.  

From a company and management team perspective, the firm seeks businesses with a strong scientific foundation, compelling and differentiated innovation, and the ability to scale. Management teams are expected to demonstrate a balanced mix of scientific expertise, business development capabilities, administrative leadership, and marketing experience. 
 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Newly Established Corporate Venture Initiative Strategically Invests in Life Sciences and AI-Powered Healthcare Technologies

3 Feb

The firm is a newly established corporate venture capital operating platform launched as part of a large global conglomerate’s corporate strategy focused on value creation and long-term growth. The firm represents the parent organization’s first company-wide corporate venture capital initiative and is designed to make flexible investments across a broad range of sectors, particularly those with large future markets and high growth potential where the parent organization can contribute differentiated value through global networks, industry and customer access, and technology and academic partnerships.  

Through the firm, the parent organization aims to accelerate collaboration with startups, identify business opportunities beyond existing core businesses, commercialize emerging technologies, support industrial application, and enable international expansion.  

The firm primarily focuses on early-stage companies, starting at Seed stage, but is able to invest across Seed through later-stage opportunities. The firm invests across a broad set of innovation-driven sectors, including AI, software, bio and healthcare, robotics, aerospace, next-generation computing, and other advanced technology domains. The investment strategy emphasizes areas where the firm can actively support commercialization, industrial deployment, and global scaling by leveraging the parent organization’s extensive industrial ecosystem.  

From a company and management team perspective, the firm partners with startups that are aligned with a broader transformation agenda and are capable of leveraging a global industrial platform to achieve scalable growth and international reach. The firm favors founding teams with deep technical expertise, strong commercialization potential, and the ability to engage effectively with industry, academic, and corporate networks. Investments are typically structured as equity participation, with active strategic support through customer access, supply-chain capabilities, and global operational resources to accelerate growth and value creation. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , , , ,

Hot Investor Mandate: Multi-Billion AUM VC Firm Invests Up to $20M in Innovative Biotech and Medtech Platforms and Products

27 Jan

A venture capital platform specialized in life sciences and medical technology manages multiple funds with total assets under management of approximately $1.5B. The firm has been operating since 2014 and is managed by a professional team with diverse and deep industry experience. To date, the firm has completed more than 90 investments in high-growth-potential companies. Typical allocation sizes for their RMB funds range from RMB 30M to RMB 150M, with the ability to invest up to RMB 200M. For the USD fund, typical investments range from $5-10M, with the ability to invest up to $20M. 

The firm is open to investing globally across the broader biomedical sector, including medtech and biotech or therapeutics. The firm focuses on technology-driven, innovative platforms and products that demonstrate clear differentiation and meaningful value creation for patients and the healthcare system overall. Within biotech and therapeutics, the firm prefers companies at the angel or venture stages, particularly those addressing significant unmet clinical needs. 

From a company perspective, the firm prefers opportunities that are technology-driven, commercially viable, and capable of solving real-world healthcare problems. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

← Older Entries
Newer Entries →